MX380972B - Moduladores de tgr5 y metodos de uso de los mismos. - Google Patents
Moduladores de tgr5 y metodos de uso de los mismos.Info
- Publication number
- MX380972B MX380972B MX2017016611A MX2017016611A MX380972B MX 380972 B MX380972 B MX 380972B MX 2017016611 A MX2017016611 A MX 2017016611A MX 2017016611 A MX2017016611 A MX 2017016611A MX 380972 B MX380972 B MX 380972B
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- formula
- methods
- compounds
- tgr5 modulators
- Prior art date
Links
- IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 title abstract 2
- 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 title abstract 2
- 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- -1 tautomer Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562182081P | 2015-06-19 | 2015-06-19 | |
| EP15305976 | 2015-06-24 | ||
| PCT/US2016/037812 WO2016205475A2 (en) | 2015-06-19 | 2016-06-16 | Tgr5 modulators and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017016611A MX2017016611A (es) | 2018-05-15 |
| MX380972B true MX380972B (es) | 2025-03-12 |
Family
ID=53489911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016611A MX380972B (es) | 2015-06-19 | 2016-06-16 | Moduladores de tgr5 y metodos de uso de los mismos. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP3310801B1 (enExample) |
| JP (1) | JP6861703B2 (enExample) |
| KR (1) | KR20180043247A (enExample) |
| CN (1) | CN107771180B (enExample) |
| AU (1) | AU2016280806B2 (enExample) |
| CA (1) | CA2989167A1 (enExample) |
| IL (1) | IL256085B (enExample) |
| MX (1) | MX380972B (enExample) |
| PL (1) | PL3310801T3 (enExample) |
| PT (1) | PT3310801T (enExample) |
| SI (1) | SI3310801T1 (enExample) |
| TW (1) | TW201700447A (enExample) |
| UY (1) | UY36738A (enExample) |
| WO (1) | WO2016205475A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2968310A1 (en) | 2014-11-19 | 2016-05-26 | NZP UK Limited | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| CN107108687B (zh) | 2014-11-19 | 2019-10-29 | Nzp英国有限公司 | 作为制备类固醇FXR调节剂的中间体的5β-6-烷基-7-羟基-3-酮类固醇 |
| KR102546748B1 (ko) | 2014-11-19 | 2023-06-22 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드 |
| TWI690536B (zh) | 2014-11-19 | 2020-04-11 | 英商Ｎｚｐ英國有限公司 | 化合物（一） |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| EP3223823A4 (en) | 2014-11-26 | 2018-10-17 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| KR20170133339A (ko) | 2015-02-11 | 2017-12-05 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법 |
| SMT202100593T1 (it) | 2015-03-31 | 2021-11-12 | Enanta Pharm Inc | Derivati degli acidi biliari come agonisti di fxr/tgr5 e metodi per il loro uso |
| JP2018519246A (ja) * | 2015-04-28 | 2018-07-19 | ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド | コール酸誘導体、及びその製造方法及び医薬用途 |
| ES2873088T3 (es) | 2015-06-19 | 2021-11-03 | Intercept Pharmaceuticals Inc | Moduladores de TGR5 y métodos para su uso |
| US20170196893A1 (en) * | 2016-01-07 | 2017-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of inflammatory demyelinating disease with agonists of farnesoid x receptor |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| US10323061B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| US10584145B2 (en) | 2016-11-29 | 2020-03-10 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| WO2018152171A1 (en) | 2017-02-14 | 2018-08-23 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr agonists and methods of use thereof |
| CN110612105B (zh) | 2017-04-07 | 2023-05-02 | 英安塔制药有限公司 | 氨基甲酸酯磺酸胆汁酸衍生物的制备方法 |
| CN109134572A (zh) * | 2017-06-19 | 2019-01-04 | 中国科学院上海药物研究所 | 胆酸衍生物及其制备方法和用途 |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| WO2020041673A1 (en) * | 2018-08-23 | 2020-02-27 | President And Fellows Of Harvard College | Compositions and methods related to cholic acid-7-sulfate as a treatment for diabetes |
| EP3890745B1 (en) * | 2018-12-04 | 2025-11-19 | President and Fellows of Harvard College | Synthetic derivatives of cholic acid 7-sulfate and uses thereof |
| WO2021046678A1 (zh) * | 2019-09-09 | 2021-03-18 | 邦泰生物工程(深圳)有限公司 | 一种合成鹅去氧胆酸的方法及其应用 |
| WO2021071837A1 (en) | 2019-10-07 | 2021-04-15 | Kallyope, Inc. | Gpr119 agonists |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| CN112300237A (zh) * | 2020-04-13 | 2021-02-02 | 苏州恩泰新材料科技有限公司 | 海豹胆酸的制备方法及其应用 |
| CN112341512A (zh) * | 2020-04-13 | 2021-02-09 | 苏州恩泰新材料科技有限公司 | 由海豹胆酸制备鹅去氧胆酸的方法 |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
| CN114276402B (zh) * | 2022-01-05 | 2023-11-14 | 厦门大学 | 一种甾体衍生物及其在制备抗肿瘤药物中的应用 |
| CN120271652B (zh) * | 2025-05-27 | 2025-10-03 | 华南理工大学 | 噁二唑-甾体化合物、药物组合物和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8410083B2 (en) * | 2007-01-19 | 2013-04-02 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as TGR5 modulators and methods of use thereof |
| EP1947108A1 (en) * | 2007-01-19 | 2008-07-23 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| CA2744189C (en) * | 2008-11-19 | 2016-10-11 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| KR101875347B1 (ko) * | 2014-06-25 | 2018-07-05 | 쓰리엠 이노베이티브 프로퍼티즈 캄파니 | 자외광-흡수 올리고머를 포함하는 감압 접착제 조성물 |
| US10208081B2 (en) * | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016086115A1 (en) * | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| EP3223823A4 (en) * | 2014-11-26 | 2018-10-17 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| JP2018519246A (ja) * | 2015-04-28 | 2018-07-19 | ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド | コール酸誘導体、及びその製造方法及び医薬用途 |
| TW201704251A (zh) * | 2015-04-29 | 2017-02-01 | 正大天晴藥業集團股份有限公司 | 鵝去氧膽酸衍生物 |
-
2016
- 2016-06-16 JP JP2018517671A patent/JP6861703B2/ja active Active
- 2016-06-16 AU AU2016280806A patent/AU2016280806B2/en active Active
- 2016-06-16 WO PCT/US2016/037812 patent/WO2016205475A2/en not_active Ceased
- 2016-06-16 PT PT167629104T patent/PT3310801T/pt unknown
- 2016-06-16 CA CA2989167A patent/CA2989167A1/en not_active Abandoned
- 2016-06-16 EP EP16762910.4A patent/EP3310801B1/en active Active
- 2016-06-16 PL PL16762910T patent/PL3310801T3/pl unknown
- 2016-06-16 TW TW105118959A patent/TW201700447A/zh unknown
- 2016-06-16 CN CN201680035575.4A patent/CN107771180B/zh active Active
- 2016-06-16 KR KR1020187001542A patent/KR20180043247A/ko not_active Withdrawn
- 2016-06-16 SI SI201631166T patent/SI3310801T1/sl unknown
- 2016-06-16 MX MX2017016611A patent/MX380972B/es unknown
- 2016-06-17 UY UY0001036738A patent/UY36738A/es not_active Application Discontinuation
-
2017
- 2017-12-04 IL IL256085A patent/IL256085B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP3310801B1 (en) | 2021-04-07 |
| SI3310801T1 (sl) | 2021-10-29 |
| IL256085B (en) | 2021-02-28 |
| AU2016280806A1 (en) | 2018-01-04 |
| AU2016280806B2 (en) | 2021-01-28 |
| CA2989167A1 (en) | 2016-12-22 |
| JP2018518537A (ja) | 2018-07-12 |
| EP3310801A2 (en) | 2018-04-25 |
| PT3310801T (pt) | 2021-06-18 |
| TW201700447A (zh) | 2017-01-01 |
| KR20180043247A (ko) | 2018-04-27 |
| CN107771180B (zh) | 2021-03-23 |
| PL3310801T3 (pl) | 2021-11-22 |
| WO2016205475A2 (en) | 2016-12-22 |
| WO2016205475A3 (en) | 2017-02-23 |
| MX2017016611A (es) | 2018-05-15 |
| IL256085A (en) | 2018-02-28 |
| CN107771180A (zh) | 2018-03-06 |
| UY36738A (es) | 2017-01-31 |
| JP6861703B2 (ja) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX380972B (es) | Moduladores de tgr5 y metodos de uso de los mismos. | |
| EA201790407A1 (ru) | Зонды для визуализации белка хантингтина | |
| EA201501142A1 (ru) | Гетероциклические соединения в качестве средств для борьбы с вредителями | |
| MX383885B (es) | Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirosina cinasa (trk). | |
| MX2016008624A (es) | Inhibidores de serina/treonina cinasa. | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
| EA201170714A1 (ru) | Модуляторы tgr5 и способы их применения | |
| EA201891009A1 (ru) | Соединения пиримидиндиона | |
| JP2014221779A5 (enExample) | ||
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| EA201790432A1 (ru) | Зонды для визуализации белка хантингтина | |
| EA201892430A1 (ru) | Синтез индазолов | |
| EA201791289A1 (ru) | Ингибиторы клеточного некроза и связанные с ними способы | |
| CY1123880T1 (el) | Καινοτομοι 5-ητ2 ανταγωνιστες | |
| EA201790400A1 (ru) | Зонды для визуализации белка хантингтина | |
| EA201790408A1 (ru) | Зонды для визуализации белка хантингтина | |
| EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 | |
| IL270552A (en) | Volclospoin composition for treating proteinuric kidney disease | |
| EA201591513A1 (ru) | Терапевтическое применение антител к vegfr1 (варианты) | |
| CL2019000487A1 (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana. | |
| EA201692518A2 (ru) | Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила | |
| EA201690294A1 (ru) | Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов | |
| CY1122418T1 (el) | Αγωγη ερυθρομελαλγιας |